Choose Language Donate to Illuminate Contact TSF
Visit us on Facebook Visit us on Twitter Visit us on YouTube Visit us on Instagram Visit us on Linkedin

Choose Your Language:

Chinese (Simplified) Chinese (Simplified) Chinese (Traditional) Chinese (Traditional) Danish Danish Dutch Dutch English English French French German German Italian Italian Portuguese Portuguese Spanish Spanish

Bienvenue Pr. Romain Marignier!

Posted by: The Sumaira Foundation in News & Announcements

November 22, 2021 – The Sumaira Foundation is pleased to welcome Professor Romain Marignier as the 1st international NMO specialist to join TSF’s medical advisory board.

Romain Marignier, MD

Pr. Romain Marignier is a neurologist (MD), professor at the Neurological Hospital of Lyon, France. His areas of expertise include neuro-inflammatory disorders of the central nervous system with a specific interest in rare disorders, namely neuromyelitis optica spectrum disorder (NMOSD) and MOG-Ab associated disease (MOG-AD).

Pr Marignier is the coordinator of the French nationwide NMOSD and MOG-AD cohorts and biobanks, NOMADMUS, set up in 2010 that includes all French clinical experts in neuro-inflammatory disorders. Through NOMADMUS, Pr Marignier provides breakthrough insights in the topic regarding clinical characterization, management, and treatment of NMOSD and MOG-AD, supported by major publications in high profile journals.

Since 2017, Pr Marignier has been the head of the French referral center for rare inflammatory disorder of the central nervous system (MIRCEM), providing expertise on diagnosis and management of NMOSD and MOG-AD for both patients and clinicians.

Finally, Pr. Marignier earned a PhD on basic neurosciences in 2011 at Claude Bernard University Lyon 1 on the role of auto-antibodies in NMOSD and related diseases. He performs his research at INSERM unit 1028 in Lyon Neuroscience Research Centre (CRNL) on: 1. The pathophysiology of auto antibody- mediated disorders of the central nervous system with in vitro, ex vivo and animal models; 2. The development of new strategies to optimise detection of auto-antibodies (anti-AQP4, anti-MOG, anti-GFAP) for diagnosis and prognosis purposes (immunohistochemistry, flow cytometry).


Industry Partners

Community Partners

WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.